Kim Young-joo, CEO of Chong Kun Dang, stated, "Wegovy is gaining attention as a groundbreaking alternative in the field of obesity treatment," adding, "We will actively expand the domestic obesity treatment market based on Chong Kun Dang's expertise in leading the markets for obesity-related diseases such as hypertension, hyperlipidemia, and diabetes, as well as successful co-promotion experiences with multinational and domestic pharmaceutical companies." Kasper Roseeuw Poulsen, CEO of Novo Nordisk Korea, said, "Wegovy is an innovative treatment developed by Novo Nordisk after more than 25 years of research, recognizing the complex epidemiological issues of obesity," and added, "Through collaboration with Chong Kun Dang, which has a strong presence in the domestic chronic disease field, we will raise awareness of Wegovy's clinical benefits and actively support domestic medical professionals to contribute to improving the treatment environment for patients struggling with obesity." Kim Min-beom AI , .
References 1 ElahiS
Woodworth JC, Minton JE, Tokach MD, Nelssen JL, Goodband RD, Dritz SS, et al
At iThriveMD, we offer competitive self-pay options
